Details

Autor(en) / Beteiligte

• Kadono, K.
• Uchida, Y.
• Hirao, H.
• Miyauchi, T.
• Watanabe, T.
• Iida, T.
• Ueda, S.
• Kanazawa, A.
• Mori, A.
• Okajima, H.
• Terajima, H.
• Uemoto, S.

Titel

Thrombomodulin Attenuates Inflammatory Damage Due to Liver Ischemia and Reperfusion Injury in Mice in Toll‐Like Receptor 4–Dependent Manner

Ist Teil von

• American journal of transplantation, 2017-01, Vol.17 (1), p.69-80

Ort / Verlag

United States: Wiley Subscription Services, Inc

Erscheinungsjahr

2017

Quelle

Electronic Journals Library

Beschreibungen/Notizen

• Liver ischemia reperfusion injury (IRI) is an important problem in liver transplantation. Thrombomodulin (TM), an effective drug for disseminated intravascular coagulation, is also known to exhibit an anti‐inflammatory effect through binding to the high‐mobility group box 1 protein (HMGB‐1) known as a proinflammatory mediator. We examined the effect of recombinant human TM (rTM) on a partial warm hepatic IRI model in wild‐type (WT) and toll‐like receptor 4 (TLR‐4) KO mice focusing on the HMGB‐1/TLR‐4 axis. As in vitro experiments, peritoneal macrophages were stimulated with recombinant HMGB‐1 protein. The rTM showed a protective effect on liver IRI. The rTM diminished the downstream signals of TLR‐4 and also HMGB‐1 expression in liver cells, as well as release of HMGB‐1 from the liver. Interestingly, neither rTM treatment in vivo nor HMGB‐1 treatment in vitro showed any effect on TLR‐4 KO mice. Parallel in vitro studies have confirmed that rTM interfered with the interaction between HMGB‐1 and TLR‐4. Furthermore, the recombinant N‐terminal lectin‐like domain 1 (D1) subunit of TM (rTMD1) also ameliorated liver IRI to the same extent as whole rTM. Not only rTM but also rTMD1 might be a novel and useful medicine for liver transplantation. This is the first report clarifying that rTM ameliorates inflammation such as IRI in a TLR‐4 pathway–dependent manner. Recombinant thrombomodulin suppresses high mobility group box‐1 protein expression in liver cells, as well as its release from the liver, and it ameliorates liver ischemia–reperfusion injury in a toll‐like receptor 4 pathway‐ dependent manner. See the editorial from Ke on page 7.